Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695500 plus chemotherapy versus rituximab plus chemotherapy in untreated follicular lymphoma
2011-002908-33Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) comparing BI 695500 plus chemotherapy with MabThera plus chemotherapy (2 arms). Primary endpoint: Best overall response rate after completion of induction therapy. Started Dec 2011; status: completed.
02
Drugs
MabionCD20rituximab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2011-002908-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002908-33.